Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240822 | 0.89 | KDM4E (0.74) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27952524 | 0.87 | KDM4E (0.72) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2022863 | 0.87 | KDM4E (0.72) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL29062416 | 0.87 | KDM4E (0.72) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1066614 | 0.86 | FFAR1 (0.70) | FFAR1PTGS1MAOB | |
| SCHEMBL19926288 | 0.85 | ALDH1A1 (0.65) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4760103 | 0.85 | MAOB (0.67) | FFAR1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4222632 | 0.84 | FFAR1 (0.68) | FFAR1PTGS1MAOB | |
| Ammonia Solution, Strong SCHEMBL27788257 | 0.84 | FFAR1 (0.68) | FFAR1PTGS1MAOB | |
| Hydrochloric Acid SCHEMBL10622121 | 0.84 | FFAR1 (0.68) | FFAR1PTGS1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303510-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2025-05-20 | — | — | US | disclosed |
| CN-119613363-A | Synthesis method of 4- (2-H-pyranoxy) phenylmalonic acid-4-methoxybenzyl monoester | 山西新天源药业有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-11213527-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2022-01-04 | — | — | US | disclosed |
| US-20210386747-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | KANONCURE, INC. (JP) | 2021-12-16 | — | — | US | disclosed |
| CN-108026104-B | Cancer and fibrosis inhibition and regeneration promotion effects using low-molecular-weight compound | 国立大学法人鸟取大学 | 2021-06-18 | — | — | CN | disclosed |
| EP-3366687-B1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NAT UNIV CORP TOTTORI UNIV (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-106132417-B | Cancer and fibrosis inhibiting effects of low molecular weight compound | 国立大学法人鸟取大学 | 2020-04-14 | — | — | CN | disclosed |
| US-10597398-B2 | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190055249-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3366687-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | National University Corporation Tottori University (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20180028536-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | KANONCURE, INC. (JP) | 2018-02-01 | — | — | US | disclosed |
| EP-3150207-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | National University Corporation Tottori University (JP) | 2017-04-05 | — | — | EP | disclosed |
| WO-2017047762-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | 国立大学法人鳥取大学 | 2017-03-23 | — | — | WO | disclosed |
| CN-106132417-A | Cancer and fibrosis inhibiting effects of low molecular weight compound | 国立大学法人鸟取大学 | 2016-11-16 | — | — | CN | disclosed |
| WO-2015147107-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | 国立大学法人鳥取大学 | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597398-B2 | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis | HDGF, SHC1, HGF | FFAR1 2851/4885POLB 3068/4885NPC1 3085/4885 |
| US-12303510-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | MMP1, SERPINB1, LGALS1 | FFAR1 3361/4885POLB 4113/4885NPC1 1707/4885 |
| US-20190055249-A1 | SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | HDGF, SHC1, HGF | FFAR1 2851/4885POLB 3068/4885NPC1 3085/4885 |
| US-11213527-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | MMP1, SERPINB1, LGALS1 | FFAR1 3361/4885POLB 4113/4885NPC1 1707/4885 |
| US-20210386747-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | MMP1, SERPINB1, LGALS1 | FFAR1 3361/4885POLB 4113/4885NPC1 1707/4885 |
| US-20180028536-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | MMP1, SERPINB1, LGALS1 | FFAR1 3361/4885POLB 4113/4885NPC1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.